





































Aging impairs organ function. Human body mass, of 
which skeletal muscle is the most abundant tissue, 
declines with age [1]. The decline in skeletal muscle 
(sarcopenia) is defined clinically by a loss of lean 
muscle mass and impairment of its function [2]. 
Adipose tissue infiltration is often observed in skeletal 
muscles of the elderly [3], and this intramuscular 
adipose tissue (IMAT) causes poor physical 
performance [4] and plays a role in insulin resistance 
and obesity [5]. Therefore, treating these conditions as 
well as sarcopenia will depend on a better 









































Skeletal muscle contains several types of SMPCs, 
including satellite cells that possess almost exclusively 
myogenic potential [6]. Adult mouse SMPCs 
spontaneously differentiate into adipocytes [7] and their 
adipogenic potential increases with age [8]. Vettor, et 
al. postulate that SMPCs form IMAT [9], thus 
suggesting that alterations in the differentiation of 
SMPCs cause sarcopenia. Differentiation of SMPCs is 
greatly affected by their microenvironment [10, 11]. For 
example, degradation of basal lamina, a major 
component of the SMPC niche, promotes adipogenic 
differentiation of SMPCs [11]. Basal lamina contains 
several extracellular matrix (ECM) proteins such as 
collagen, laminin, fibronectin and proteoglycans. ECM 
proteins function as structural supports for  SMPCs  and  
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and  adipogenesis.  Secreted  protein  acidic  and  rich  in  cysteine  (SPARC),  which  is  secreted  from  SMPCs,  stimulates
myogenesis and inhibits adipogenesis. The present study aimed to examine whether changes in SPARC expression, its
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SPARC (also known as osteonectin or BM-40) is a 
nonstructural, matricellular glycoprotein that is secreted 
into the niche and functions in cell adhesion, 
angiogenesis, growth factor binding, and cell 
differentiation [13, 14]. SPARC inhibits adipogenesis of 
preadipocytes by enhancing β-catenin signaling [15]. It 
also promotes myogenic differentiation of C2C12 and 
MM14 myoblasts [16, 17]. SPARC is expressed by 
SMPCs [18] and may regulate SMPC function in an 
autocrine manner. SPARC-null mice exhibit early-onset 
cataracts [19], osteopenia-like decline of bone 
formation [20], increased obesity, and decreased 
skeletal muscle mass [21]. These phenotypes are 
typically observed in old mice. 
 
In the present study, we examined whether changes in 
SPARC expression or signaling are involved in age-





SMPCs express SPARC regardless of their 
differentiation state during myogenesis and 
adipogenesis 
 
SMPCs express SPARC [18] and can differentiate into 
myogenic and adipogenic cells [7]. To examine whether 
the expression of SPARC by SMPCs is differentiation 
dependent, we immunostained SMPCs derived from 
young rats by using antibodies specific for MyoD, 
C/EBPα, myosin heavy chain (MHC), and SPARC 
(Figure 1). MyoD is a transcription factor that plays a 
critical role in myogenesis. MyoD-positive cells 
coexpressed SPARC in SMPC cultures 3 days after 
plating. MHC-positive myotubes, induced by culturing 
SMPCs in media containing 2% HS, were also positive 
for SPARC. Approximately 20% of SMPCs expressed 
C/EBPα-, a transcription factor involved in adipo-
genesis, and were stained with Oil Red-O, an indicator 
of adipogenesis. Both C/EBPα- and Oil Red-O-positive 
cells expressed SPARC. In all cases, SPARC expression 
was detected in both non-myogenic and non-adipogenic 
cells, indicating that SMPC express SPARC regardless 
of their state of differentiation. 
 
SPARC expression levels in SMPCs do not change 
with age 
 
The adipogenic potential of SMPC increases with age 
[8], which we confirmed here (data not shown). 
Because SPARC inhibits adipogenesis [15], the age-














































may be due to a decline in their secretion of SPARC. 
However, quantitative PCR analysis revealed no 
differences in SPARC expression levels between 
SMPCs from young and old rats (Figure 2A). 
Immunoblotting and immunostaining of SPARC in 
young and old SMPCs also showed that the levels of 
SPARC expression in SMPCs does not change with age 
(Figures 2B and 2C). These results suggest that the 
increased adipogenic potential of old SMPCs is not 
caused by a decline in SPARC. 
Figure.  1. Immunocytochemistry  of  SPARC  in  SMPCs.
Immunostaining  of  SPARC  during  myogenic  and  adipogenic
differentiation  of  SMPCs  from  young  rats.  Cells  were  co‐
stained with anti‐MyoD and anti‐SPARC 3 days after plating or
with anti‐MHC and anti‐SPARC 4 days after exposure to media
containing  2%  HS.  Co‐staining  with  anti‐SPARC  and  anti‐
C/EBPα  or  Oil  Red  O  staining  was  performed  4  days  after
culturing  in  the  media  to  induce  adipogenic  differentiation
(ADM). Nuclei were visualized with Hoechst 33258 Dye (blue).
White  arrowheads  indicate  double‐positive  cells
(MyoD+/SPARC+,  MHC+/SPARC+,  C/EBPα+/SPARC+,  and  Oil
Red O+/SPARC+), whereas black arrowheads indicate cells that
are  only  positive  for  SPARC  (MyoD‐/SPARC+,  MHC‐/SPARC+,
C/EBPα‐/SPARC+, and Oil Red O‐/SPARC+). Scale bar = 100 μm. 
   







































The efficiency of RNA silencing of SPARC is 
independent of SMPC age. 
 
Despite the anti-adipogenic function of SPARC [15], 
there was no difference in the expression of SPARC as 
a function of SMPC age. This raises the possibility that 
responsiveness of SMPCs to SPARC, rather than its 
expression, declines with age. To examine this, we 
employed the siRNA for SPARC (siSPARC) in an 
attempt to down-regulate SPARC. First, we determined 
the knockdown efficiency of siSPARC in young and old 
SMPCS by qPCR and immunoblotting. One day after 
siSPARC transfection, SPARC gene expression was 
silenced by more than 90% in young and old SMPCs 
(Figure 3A). Immunoblotting revealed that the amount 
of SPARC was reduced to a similar extent in cells 
derived from young and old rats (Figure 3B). These 
results indicate that the efficiency of siRNA-mediated 








































Effects of SPARC knockdown on the differentiation 
of SMPCs diminish with age. 
 
We next evaluated the adipogenic potential of young 
and old SMPCs when SPARC expression was reduced 
by its cognate siRNA (Figure 4). In young SMPCs 
transfected with siSPARC, the Oil Red-O-positive area 
was increased, suggesting that SPARC suppresses 
adipogenesis (Figure 4A). In contrast, no changes were 
observed in old SMPCs. Adipogenesis was also 
evaluated by immunostaining for C/EBPα, a 
transcription factor whose levels increase with 





(B)  Immunoblotting  analysis  of  SPARC  expression  levels  in
SMPCs from young and old rats 3 days after plating. Data are
expressed  as  mean  ±  SEM  (n  =  3,  respectively).  (C)
Representative immunostaining experiments to detect SPARC
expression  in  SMPCs  from  young  and  old  rats  3  days  after
plating (left). Scale bar = 100 μm. A plot of the proportions of
nuclei  in  SPARC‐positive  cells  is  shown  (right).  Data  are
expressed as the mean ± SEM (n = 3, respectively). 
Figure 3. Inhibition of SPARC expression by RNA silen‐
cing  in  young  and  old  rat  SMPCs.  (A)  The  efficiency  of 
silencing  by  siSPARC  was  evaluated  by  qPCR  in  SMPCs  from 
young  and  old  rats  2  days  after  siRNA  transfection.  Data  are 
expressed as the mean ± SEM (n = 4, respectively). *p < 0.05 vs. 
control. (B) The efficiency of siSPARC silencing was evaluated by 
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endogenously produced SPARC inhibits adipogenesis 
of SMPC, but this effect diminishes with age, 







































SPARC activates myotube formation [16, 17]. Thus, we 
examined whether decreased SPARC expression altered 
myogenesis in SMPCs. Young and old SMPCs were 
transfected with siSPARC, and myogenesis was 
evaluated by immunostaining for myogenin and MHC, 
which serve as markers for terminal myogenic differen-
tiation. In young SMPCs, silencing of endogenous 
SPARC expression reduced the proportion of myogenin-
positive cells (Figure 5A) and nuclei in MHC-positive 
cells (Figure 5B). In contrast, no statistically significant 
effects were observed in old SMPCs. These results 
suggest that SMPCs activate their myogenesis but that 




































The responsiveness of SMPCs to exogenously added 
SPARC diminishes with age 
 
We investigated whether exogenous addition of SPARC 
to SMPCs inhibits adipogenesis and promotes myo-
genesis when endogenous SPARC is downregulated by 
siRNA. As shown in Figure 6, addition of 20 μg/ml 
SPARC decreased adipogenesis by approximately 60% 
(Figure 6A) and increased myogenesis by 6-fold (Figure 
6B) in young SMPCs, whereas this did not affect old 
SMPC cultures. These results suggest that old SMPCs 
are less sensitive to exogenous SPARC, and further 
support the notion that responsiveness of SMPC to 
SPARC declines with age. 
 
Expression of the integrin alpha-5 component of the 
SPARC receptor is decreased on old SMPCs 
 
Heterodimers composed of integrin α5 (ITGA5) and 
integrin β1 (ITGB1) serve as the receptor for SPARC 
Figure 4. Effects of siSPARC on the adipogenic potential
of  SMPCs.  (A)  Representative  Oil  Red‐O  staining  of  SMPCs






for  4  days  in  differentiation  media  (above),  and  quantitative








(above)  and  quantitative  analysis  of  myogenin‐positive  cells
(below).  Nuclei  were  counterstained  with  Hoechst  33258.
White arrowheads indicate myogenin‐positive nuclei. Scale bar
=  100  μm.  Proportions  of  myogenin‐positive  cells  were
calculated and ratios to. control values are graphed. Data are
expressed as mean ± SEM (n = 4, respectively). *p < 0.05 vs.
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possibility that the age-related decline in SPARC 
responsiveness is caused by a loss of ITGA5 and/or 
ITGB1. Quantitative PCR analysis revealed an 
approximately 50% decrease in the Itga5 expression 
level in old compared with young SMPCs, but not Itgb1 
expression level (Figure 7A). We next determined 
whether decreased ITGA5 expression contributed to the 
age-related decline of SPARC responsiveness. Most 
young SMPCs were stained strongly by an ITGA5 
antibody, whereas only approximately 20% of the old 
SMPCs were stained at an intensity similar to that of 
young SMPCs. The remaining cells were faintly stained 
(Figure 7B). We then quantified ITGA5 expression 
levels in young and old SMPCs by immuno-
fluorescence. As shown in Figure 7C, fluorescence 
decreased by approximately 50% in old compared with 










































































Next, we employed siRNA technology to test whether 
ITGA5 is involved in the role of SPARC in regulating 
SMPC differentiation. Itga5 mRNA and protein 
expression in siItga5-treated young SMPCs were 
evaluated by qPCR and immunocytochemistry, 
respectively. Transcript and protein levels decreased by 
approximately 50% compared with controls (Figures 8A 
and 8B), similar to their levels in old SMPCs (see 
Figure 7). Itga5-knockdown enhanced adipogenesis and 
inhibited myogenesis, and concomitant transfection of 
siSPARC did not significantly affect the differentiation 
of siItga5-treated young SMPCs (Figures 8C and 8D). 
When ITGA5 expression was inhibited by siRNA 
transfection, the anti-adipogenic effect of exogenous 
SPARC was not observed (Figure 8E). In contrast, we 
detected a statistically significant 2-fold increase in 
myogenesis by recombinant SPARC even when ITGA5 
expression was reduced (Figure 8F). Therefore, 
although the anti-adipogenic effect of SPARC in 
Figure  6.  Effects  of  exogenously  added  SPARC  on
differentiation  of  SMPCs  with  diminished  levels  of
SPARC  expression.  SMPCs  from  young  and  old  rats  were
cultured for 4 days in adipogenic media in the presence of BSA
(20  μg/ml)  or  recombinant  SPARC  (20  μg/ml)  1  day  after
transfection with siSPARC. (A) Oil Red‐O‐positive areas were
quantified as pixel values and the ratios to control values are
graphed.  Data  are  expressed  as  mean  ±  SEM  (n  =  3,
respectively). *p < 0.05 vs. BSA‐treated cells. (B) Proportions of
MHC‐positive cells were calculated and ratios to control values
are  graphed.  Data  are  expressed  as  mean  ±  SEM  (n  =  3,
respectively). *p < 0.05 vs. BSA treated cells. 
Figure 7. Itga5 mRNA and protein expression in young
and  old  rat  SMPCs.  (A)  qPCR  analysis  of  Itga5  and  Itgb1
expression  in  SMPCs  from  young  and  old  rats  3  days  after
plating.  Graphed  data  are  expressed  as  mean  ±  SEM  (Itga5:
young; n = 4, old; n = 6, Itgb1: n = 4, respectively). *p < 0.05 vs.
young.  (B)  Typical  immunostaining  of  ITGA5  in  SMPCs  from
young  and  old  rats  3  days  after  plating.  Nuclei  were
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its pro-myogenic effect may also be exerted through 
other SPARC receptors. These findings suggest that the 
age-related decline in SPARC responsiveness in SMPC 
adipogenesis is caused by decreased ITGA5 expression, 
whereas other molecules are involved in decreased 















































Here, we demonstrate for the first time to our 
knowledge that the responsiveness of SMPCs to 
SPARC declines with age, and may contribute to the 
age-related phenotypic changes in SMPCs. Because 
SPARC enhances myogenesis and inhibits adipogenesis 
[15, 16, 17], we reasoned that its decreased expression 
or alterations in its signaling pathway in SMPCs 
contribute to age-related dysfunction of skeletal muscle, 
such as fatty infiltration [8, 9] and impaired muscle 
regeneration [23]. The present study shows that the 
SPARC signaling pathway, rather than the level of its 
expression in SMPCs changes with age. It should be 
noted skeletal muscle cell types other than SMPCs, such 
as myofibers and endothelial cells, express SPARC 
[18]. Moreover, SPARC expression levels decline with 
age in the skeletal muscles of mice [24]. This indicates 
that although SPARC expression in SMPCs is not 
altered with age, the amount of SPARC available in the 
SMPC microenvironment would be decreased. Thus, it 
is possible that in addition to the decreased 
responsiveness of SMPC to SPARC, the age-related 
decline of SPARC expression levels in skeletal muscle 
accelerates age-related phenotypic changes in SMPC. 
 
The present study suggests the decline in SPARC 
responsiveness in adipogenesis as a function of age was 
caused by the decreased expression of ITGA5, a subunit 
of the SPARC receptor of adipose stromal cells [22]. 
SPARC binds to ITGB1, resulting in activation of 
integrin-linked kinase (ILK), which interacts with the 
cytoplasmic tails of ITGB-subunits [25]. SPARC 
inhibits adipogenesis by promoting ILK activation and 
subsequent nuclear translocation of β-catenin [15], 
suggesting that the anti-adipogenic effect of SPARC is 
mediated by the ITGA5-ITGB1 complex. Senescent 
fibroblasts isolated from patients with Werner 
syndrome, a premature aging disorder [26], express 
reduced levels of ITGA5. These findings support the 
conclusion that ITGA5 expression levels are linked to 
aging, which is in agreement with our results presented 
here.  
 
The present study suggests that molecules other than 
ITGA5 may be involved in the age-related decline in 
SPARC responsiveness during myogenesis. Several cell 
surface molecules are capable of binding to SPARC 
[27, 28]. Stabilin-1, a scavenger receptor, is expressed 
in tissue macrophages, interacts with SPARC and plays 
a role in the internalization of SPARC by endocytosis 
[27]. Vascular cell adhesion molecule (VCAM)-1, the 
regulator of adhesion of leukocytes to the vascular 
endothelium, also interacts with SPARC derived from 
leukocytes [28] and is expressed in C2C12 myoblasts 
Figure. 8. Knockdown of ITGA5 expression in young SMPCs
by  siRNA  transfection.  (A)  Efficiency  of  siRNA  silencing  was




after  transfection  with  siItga5.  Graphed  data  are  expressed  as
mean  ±  SEM  (n  =  3,  respectively).  *p  <  0.05  vs.  control.
Quantitative  analysis  of  Oil  Red‐O  staining  results  (C)  and
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inhibition of myotube formation, suggesting that 
VCAM-1 is an element required for myogenesis of 
SMPCs. However, whether expression levels of either 
stabilin-1 or VCAM-1 in SMPCs change with age is 
unknown. Further studies are needed to identify the 
molecules that are involved in SPARC-resistance in 
myogenesis of SMPCs as a function of age. 
 
It was shown that overactivation of mTOR causes 
feedback resistance to insulin and growth factors [30, 
31]. It was suggested that signal-resistance is a hallmark 
of aging/senescent cells due to chronic increase in basal 
activity of the mTOR pathway [32, 33, 34]. In turn, 
such signal resistance may be abrogated by intermittent 
pulse-treatment with rapamycin [32]. In fact, 
normalization of mTOR may prevent sarcopenia [35]. 
Thus, the current observation that old SMPCs show 
refractory to SPARC may be caused by age-related 
overactivation of mTOR. 
 
In summary, we show here an age-related decline in the 
responsiveness of SMPCs to SPARC, and suggest that 
this may be a cause of the age-related phenotypic 
changes in SMPC that could lead to IMAT 
accumulation. Further investigations into the nature of 
SPARC resistance should provide useful information 




Animals. Young (age, 4 to 5 months) and old (age, over 
21 months) male Wistar-Imamichi rats were used in this 
study. All animals were bred in our laboratory under 
controlled environmental conditions: 23°C with a 
photoperiod of 12-h light and 12-h darkness (lights on 
at 0700 hours). Animals were fed ad libitum with 
commercial chow (Lab MR-Breeder Standard Nihon 
Nosan Kogyo, Yokohama, Japan). All animal 
experiments in this study were performed in accordance 
with the Guide for the Care and Use of Laboratory 
Animals of the University of Tokyo, and were approved 
by the Institutional Animal Care and Use Committee of 
the University of Tokyo. 
 
SMPC isolation and culture. SMPCs were isolated from 
the hindlimb and back muscles of rats according to 
published procedures [36, 37]. To examine adipogenic 
potential, SMPCs were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS) and penicillin/streptomycin  (10% 
FBS/DMEM) supplemented with insulin (1 μg/ml), 
dexamethasone (0.1 μg/ml), isobutylmethylxanthine 
(27.8 μg/ml), and troglitazone (10 μM, kindly donated 
by Daiichi Sankyo Co., Ltd.) for 2 days, followed by 
culture for 2 days in 10% FBS/DMEM supplemented 
with insulin and troglitazone, and culture for 4 days in 
10% FBS/DMEM supplemented with troglitazone. To 
examine myogenic potential, SMPCs were cultured for 
4 days in DMEM containing 2% horse serum (HS) and 
supplemented with antibiotics. 
 
Quantitative PCR (qPCR). RNA was isolated from cells 
3 days after plating using TRIzol (Invitrogen, Carlsbad, 
CA, USA), and cDNA was synthesized using 
SuperScriptII reverse transcriptase (Invitrogen). 
Quantitative PCR was performed using Thunderbird 
probe qPCR (TOYOBO, Osaka, Japan) with the probes 
(Roche, Basel, Switzerland) corresponding to the genes 
detected on Light Cycler (Roche). PCR was performed 
using the following primers: SPARC (forward, 5′-
aggtgcagaggaaactgtcg-3′; reverse, 5′-gtttgcagtgatggttc 
tgg-3′), integrin α5 (Itga5) (forward, 5′-gcaccattcaatt 
tgacagc-3′; reverse, 5′-ttgtactccacaggttcctcac-3′), 
integrin β1 (Itgb1) (forward, 5′-atcatgcaggttgcagtttg-3′; 
reverse, 5′-cgtggaaaacaccagcagt-3′), hypoxanthine 
guanine phosphoribosyltransferase (Hprt) (forward, 5′-
gaccggttctgtcatgtcg-3′; reverse, 5′-acctggttcatcatcacta 
atcac-3′). 
 
RNA interference. RNA interference was carried out 
with siRNA duplexes designed to target rat SPARC and 
rat ITGA5 (Sigma-Aldrich, St. Louis, MO, USA). 
Negative control siRNA (Stealth RNAi Negative 
Control Duplexes, Invitrogen) was also used. Two or 3 
days after plating, cells were transfected with siRNAs 
by using Lipofectamine RNAi Max (Invitrogen) 
according to the manufacturer’s instructions. One day 
after transfection, media were replaced with 
differentiation media in order to examine adipogenic or 
myogenic potential. In some experiments, recombinant 
mouse SPARC (120-36, PeproTech, Rocky Hill, NJ, 
USA) was added during adipogenic differentiation for 4 
days after siRNA transfection. An equal amount of 
bovine serum albumin (BSA) (Sigma) was used as a 
control. To evaluate the efficiency of gene silencing by 
SPARC siRNA (siSPARC), RNA and protein samples 
were extracted from SMPCs 2 days after transfection, 
and SPARC expression was confirmed by qPCR and 
immunoblotting. The efficiency of gene silencing by 
Itga5 siRNA (siItga5) was confirmed by qPCR and 
immunocytochemistry 2 days after transfection. 
 
Immunoblotting. SMPCs were lysed in sample buffer 
(0.5 M Tris-HCl, 10% Glycerol, 1% sodium dodecyl 
sulfate (SDS), and 10% 2-mercaptoethanol). Protein 
extracts were separated on SDS-polyacrylamide gel and 
then transferred to polyvinylidene fluoride membranes. 
SPARC protein was detected using an anti-SPARC 
rabbit polyclonal antibody (A08332, Sigma-Aldrich), 
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labeled secondary antibody and ECL detection system 
(GE Healthcare Biosciences, Piscataway, NJ, USA). 
Blots were then reprobed with anti-β-actin antibody 
(mouse monoclonal antibody, A1978, Sigma) as a 
loading control. 
 
Immunocytochemistry. For immunocytochemical 
detection of SPARC, MyoD, myogenin, myosin heavy 
chain (MHC), and ITGA5, cultured SMPCs were fixed 
in 4% paraformaldehyde in phosphate buffered saline 
(PBS) at room temperature (RT) for 15 min. For 
detection of C/EBPα, cells were fixed in methanol. 
After fixation, the cells were washed 3 times with PBS, 
followed by blocking with 5% normal goat serum /PBS 
containing 0.1% Triton-X 100 (Sigma) for 20 min at 
RT. When methanol was used for fixation, Triton-X 100 
was omitted from the blocking solution. Donkey serum 
was used in place of normal goat serum for the 
detection of SPARC. Cells were reacted with primary 
antibodies (described below) overnight at 4°C. After 3 
washes with PBS, the cells were incubated with 
AlexaFluor-conjugated secondary antibodies 
(Invitrogen, 1:500 dilution) for 1 h at RT. Nuclei were 
counterstained with Hoechst 33258. Observations were 
performed using a fluorescence microscope (BX50, 
Olympus, Tokyo, Japan) equipped with a digital camera 
(DP70, Olympus). For quantitative analysis of 
differentiation, the number of SPARC-positive cells; the 
number of nuclei in C/EBPα-, myogenin-, or MHC-
positive cells; and total nuclei were counted in 5 
randomly selected fields using a 10× objective in order 
to calculate the proportion of positive cells. The 
fluorescence intensity of ITGA5 was quantified using 
ImageJ software (ver.1.43, NIH). 
 
Primary antibodies and their species of origin were as 
follows: anti-SPARC (goat, R&D systems, 
Minneapolis, MN, USA, 1:100 dilution); anti-MyoD 
(mouse, clone A5.8, Novocastra, Newcastle upon Tyne, 
UK, 1:100 dilution), anti-C/EBPα (rabbit, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA, 1:200 dilution), 
anti-myogenin (mouse, clone F5D, hybridoma 
supernatant, Developmental Studies Hybridoma Bank, 
Iowa City, IA, USA, 1:200 dilution), anti-MHC (mouse, 
clone MF20, hybridoma supernatant, Developmental 
Studies Hybridoma Bank,  1:200 dilution), and anti-
ITGA5 (rabbit, AB1928, Millipore, Bedford, MA, USA, 
1:1000 dilution). 
 
Oil Red-O staining. Oil Red-O staining was used for 
detection of accumulated cellular lipid droplets, which 
represent the adipogenic potential of SMPCs. SMPCs 
were fixed in 4% paraformaldehyde in PBS for 15 min 
at RT, rinsed 3 times with PBS, stained with Oil Red-O 
mixture (2:3 mixture of 0.5% (w/v) Oil Red-O (Sigma) 
in 2-propanol and distilled water) for 10 min. For 
quantification of adipogenesis, 5 different fields 
randomly chosen under the microscope using a 10× 
objective were photographed, and the areas stained with 
Oil Red-O were quantified using ImageJ software. 
Values representing the incidence of adipogenesis were 
expressed as mean pixel measurements. 
 
Statistical analyses. ANOVA followed by Tukey-
Kramer post-hoc comparisons were used to evaluate 
statistical differences among the groups. Student’s t-test 
was used to examine differences between the 2 groups. 
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